Ibrutinib: neuropatía periférica / triamcinolona nasal: coriorretinopatía, visión borrosa
emc, de agosto de 2018
REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe
At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields.
FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...
FDA - U.S. Food and Drug Administration